Draft Guidance for Industry: Investigational New Drug Applications; Determining Whether Human Research Studies Can be Conducted Without an Invertigational New Drug Application
Document ID: FDA-2010-D-0503-0001
Comments
Total: 10
-
Anonymous - Comment
Posted : 11/19/2010 ID ：FDA-2010-D-0503-0003 Agency : FDA -
Jan 12,2011 11:59 PM ET
-
Joan Cobb Pettit - Comment
Posted : 11/19/2010 ID ：FDA-2010-D-0503-0004 Agency : FDA -
Jan 12,2011 11:59 PM ET
-
Council for Responsible Nutrition (CRN) - Comment
Posted : 01/18/2011 ID ：FDA-2010-D-0503-0006 Agency : FDA -
Jan 12,2011 11:59 PM ET
-
Consumer Healthcare Products Association (CHPA) - Comment
Posted : 01/18/2011 ID ：FDA-2010-D-0503-0007 Agency : FDA -
Jan 12,2011 11:59 PM ET
-
International Scientific Association for Probiotics & Prebiotics - Comment
Posted : 01/18/2011 ID ：FDA-2010-D-0503-0009 Agency : FDA -
Jan 12,2011 11:59 PM ET
-
AstraZeneca - Comment
Posted : 01/18/2011 ID ：FDA-2010-D-0503-0010 Agency : FDA -
Jan 12,2011 11:59 PM ET
-
Merck Sharp & Dohme, Corp - Comment
Posted : 01/18/2011 ID ：FDA-2010-D-0503-0011 Agency : FDA -
Jan 12,2011 11:59 PM ET
-
Primus Pharmaceuticals, Inc. - Comment
Posted : 01/18/2011 ID ：FDA-2010-D-0503-0012 Agency : FDA -
Jan 12,2011 11:59 PM ET
-
Natural Products Association - Comment
Posted : 01/18/2011 ID ：FDA-2010-D-0503-0013 Agency : FDA -
Jan 12,2011 11:59 PM ET
-
University of Maryland School of Law - Comment
Posted : 02/15/2011 ID ：FDA-2010-D-0503-0014 Agency : FDA -
Jan 12,2011 11:59 PM ET